01 Growing Use of Chemiluminescence Immunoassays over Traditional Elisa Methods The global immunoassay market is witnessing a significant shift toward chemiluminescence immunoassays (CLIA) due to their higher sensitivity, precision, and faster turnaround times compared to traditional ELISA methods. CLIA is increasingly adopted in hospitals, laboratories, and point-of-care settings to support early disease detection and monitoring. In February 2025, at Medlab Middle East in Dubai, Wondfo showcased its expanded chemiluminescence immunoassay portfolio, highlighting the SmarLumi™ FC-2100 analyzer and ACCRE mono-test CLIA platform. The FC-2100 delivers a throughput of up to 200 tests per hour with first results available in 12 minutes, while the company also expanded its chemiluminescence menu to nearly 100 diagnostic assays, supporting broader applications in infectious diseases, cardiac biomarkers, endocrinology, and oncology Such innovations highlight the rising preference for CLIA systems globally.
02 Growing Adoption of Point-of-Care Immunoassays The growing adoption of point-of-care immunoassays is significantly boosting the global market, as these tests provide rapid, accurate, and convenient disease detection at decentralized healthcare facilities. Their increasing use in managing infectious diseases, chronic conditions, and emergency care is enhancing diagnostic efficiency and patient outcomes. For instance, in July 2025, Anbio Biotechnology Ltd. unveiled the Anbio AF-100S, a compact, automated, and affordable fluorescent immunoassay (FIA) analyzer designed for rapid point-of-care testing. Such innovations strengthen accessibility, enabling timely treatment decisions and driving global immunoassay market growth.
01 Rising Prevalence of Chronic and Infectious Diseases Worldwide The global market is strongly driven by the rising prevalence of chronic and infectious diseases, creating a growing demand for reliable diagnostic tools. Chronic conditions and infectious outbreaks continue to burden healthcare systems, necessitating advanced testing solutions for early detection and effective management.Immunoassays, with their high sensitivity and specificity, play a crucial role in monitoring disease progression, guiding treatment, and improving patient outcomes globally.
02 Growing Demand for Early and Accurate Disease Diagnosis The global immunoassay market is significantly driven by the rising need for early and precise disease detection to improve treatment outcomes. Immunoassays provide high sensitivity and specificity, making them indispensable in diagnosing chronic and infectious diseases.
01 High Cost of Advanced Systems and Reagents The high cost of advanced immunoassay systems and reagents remains a significant restraint to market growth, particularly in resource-limited settings. These systems require prominent investment in both equipment and consumables, making affordability a challenge for smaller laboratories and healthcare facilities.Additionally, recurring expenses for specialized reagents and maintenance further increase the financial burden, restricting wider adoption in developing regions.
01 Expanding Immunoassay Applications in Veterinary Diagnostics The veterinary diagnostics sector is emerging as a significant growth avenue for immunoassays, driven by rising awareness of animal health and the increasing prevalence of zoonotic and infectious diseases among pets and livestock. Immunoassays offer rapid, accurate, and cost-effective diagnostic solutions for veterinary clinics and research laboratories.Such advancements highlight a widening opportunity to diversify applications and capture growth in emerging diagnostic segments.
March 2026 Roche expanded its immunoassay diagnostics portfolio with new laboratory testing solutions designed to improve automation, accuracy, and efficiency in clinical diagnostics.
September 2025 Abbott introduced enhanced immunoassay technologies for its diagnostic platforms, supporting faster and more reliable testing across infectious diseases, cardiology, and other clinical applications.
May 2025 Siemens Healthineers expanded its immunoassay testing capabilities with upgraded laboratory diagnostic solutions focused on improved workflow automation and patient testing efficiency.